TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01096654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ct-scan or adrenal vein sampling
Description: Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ct-scan or adrenal vein sampling
Description: Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
Study: NCT00589589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endo Tool
Description: Computer tool to help achieve glucose control
Study: NCT04528160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care delivered at primary care for older adults with pain.
Study: NCT01606072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 20 patients in 5 groups 4 each, advancing progressively to each dose level.
Study: NCT01001975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-028
Description: Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-028
Description: Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-030
Description: Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-030
Description: Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard SPF 4 Sunscreen
Description: 8% Homosalate Standard SPF 4 Sunscreen
Study: NCT01662167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single
Description: In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multipe
Description: In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
Study: NCT03769662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study: NCT04539080

Intervention type: PROCEDURE
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block group
Study: NCT00483496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoctrizole 10% alone (formula RV3131A-MV1237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)
Study: NCT02413307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy (self-practice)
Description: Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
Study: NCT04084171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Description: Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
Study: NCT03710746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
Study: NCT00483496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0096 CR vehicle (formula RV3131A-MV1197)
Study: NCT03710746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
Study: NCT00052585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT03769480

Intervention type: OTHER
Intervention: Muscle strength evaluation and Respiratory function Tests
Description: Muscle strength evaluation and Respiratory function Tests

Intervention type: OTHER
Intervention: Muscle strength evaluation and Respiratory function Tests
Description: Muscle strength evaluation and Respiratory function Tests
Study: NCT00052585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT02995980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Contrast-Enhanced (DECE) mammography
Description: Contrast mammography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: routine digital mammography
Study: NCT03326804

Intervention type: DEVICE
Intervention: H1 Hip Resurfacing Arthroplasty
Description: A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device

Intervention type: DEVICE
Intervention: H1 Hip Resurfacing Arthroplasty
Description: A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
Study: NCT00999544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 0mg
Description: Aprepitant 0mg, p.o. pretreatment
Study: NCT03481309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal tDCS
Description: The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
Study: NCT01775020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Study: NCT03868137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 doses of Ibuprofen 800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT01254409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
Study: NCT02072759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnitine supplement
Description: Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01627366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan
Description: Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
Study: NCT04491149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
Study: NCT03492359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thora-3Di
Description: Device that uses a grid of structured light to measure chest and abdominal wall movement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thora-3Di
Description: Device that uses a grid of structured light to measure chest and abdominal wall movement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Plethysmography
Description: A pulmonary function test (PFT) for measuring total lung volume.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Plethysmography
Description: A pulmonary function test (PFT) for measuring total lung volume.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
Study: NCT03065309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: bolus dose
Study: NCT02044783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Study: NCT02369809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen®
Description: Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neovasculgen®
Description: Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
Study: NCT00262600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran dose 1
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran dose 2
Description: twice a day
Study: NCT03307239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tap water packs application
Description: We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application.
Study: NCT04452968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
Study: NCT01310465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride, 100ml, intravenous, one time at three days postoperatively
Study: NCT01555372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hook Plate
Description: All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locking Plate
Description: All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
Study: NCT02222610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Retinal Photocoagulation (TRP)
Description: TRP to areas of retinal ischemia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Retinal Photocoagulation (TRP)
Description: TRP to areas of retinal ischemia
Study: NCT01735266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air colonoscopy
Description: Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Description: Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Description: Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
Study: NCT04085549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Berry Oil Cream
Description: Cream containing berry and plant oils and humectants; a medical device product in development

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference Cream
Description: Commercial refence cream not containing berry and plant oils.
Study: NCT04310111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA
Description: Use EUS-RFA to treat unresectable pancreatic cancer
Study: NCT01072188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arginine/Calcium Carbonate
Description: One time treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nupro - Fluoride Free
Description: Brush twice daily
Study: NCT01400698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® A
Description: Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® B
Description: Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation only
Description: Subjects were only observed.
Study: NCT00487357

Intervention type: BEHAVIORAL
Intervention: Supplemental Survey
Description: Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
Study: NCT02851641

Intervention type: PROCEDURE
Intervention: pushed mono-canaliculonasal intubation
Study: NCT03260257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
Study: NCT00660543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium
Description: Given IV
Study: NCT03481335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHAP-P Sessions
Description: Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
Study: NCT00660543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Non-Stoichiometric Magnetite
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI